Clinical Net was born

After 12+ years working on academic research and drug development in oncology and experiencing the limitations and inefficiencies of clinical drug development, our founder Nuria envisioned a paradigm shifting solution for gathering, managing, and sharing clinical trial information. A solution that will radically change how clinical trials are designed, set up and managed, how patients can access emerging therapies, and how patient health information is stored and accessed worldwide.

Our mission

Committed to making clinical trials widely accessible and change the world’s clinical drug development paradigm by creating a worldwide central platform with an orchestrated set of solutions to bring ground-breaking therapeutic options quicker to humankind.

The platform

Clinical Net is developing a platform designed to digitalise and automate clinical trial processes in order to facilitate access for patients, improve trial recruitment and success rate, and ultimately reduce costs and accelerate time associated with drug development.

By aggregating and structuring complex clinical trial data from different sources we can provide a robust information pipeline that can facilitate digitalisation and automation across the clinical trial processes and leverage patient health information in one single platform.

Clinical Net platform will be deployed in four phases. In phase 1, the platform will enclose a set of tools and features to allow patients to easily identify the right trials for them, trial sites to quickly recruit the right patients, and investigators to effectively collect and manage trial data.


Why now?

Never before have a drug, vaccine or medical device been approved for use as rapidly as vaccine candidates for Covid-19. The astonishing pace of progress in the development of these vaccines is due to several reasons:

  • The previous work done with similar viruses like SARS-1 is giving scientists a head start for crafting their candidates
  • Trials have been collapsed into Phase 1/2 or Phase 2/3 trials, saving research teams from having to write new protocols or get additional clearances
  • The massive number of volunteers to join clinical trials for Covid-19 due to the worldwide known colossal impact of the virus significantly reduced recruitment times, a well-known limiting factor in trials
  • Regulatory bodies have expedited regulatory decisions on clinical trials permissions and proactively engaged in communications with companies about the efficacy thresholds products needed to meet for approval, shortening the trial design process

On top of these shortcuts in clinical development, governments and foundations have thrown millions to motivate companies to start manufacturing the vaccines while these were in clinical trials so they could be rolled out to as many people as quickly as possible once these were proven to be safe and effective. Consequently, the first Covid-19 vaccine became available only months after the virus emerged instead of the usual 10+ years previously reported for drug development.

This clearly proves that the standard drug development process has the potential to be accelerated, bringing new therapies to patients sooner and lowering the cost of drug development. While it may not be possible to apply all these efficiencies in the to development of every single new drug, there are several key steps that can be optimised to shorten the timeline needed to bring any drug to market.

Leadership & Advisory Board

Foto Nuria Clear Background

Nuria Coll Bastus


Denis Talbot Clinical Net

Prof. Denis Talbot


David Farrugia Photo

Dr. David Farrugia


Janette Rawlinson Clinical Net

Janette Rawlinson


Tim Musson Clincal Net

Tim Musson


Filippo Lanza Clincal Net

Filippo Lanza